Compare ADMA Biologics Inc (ADMA) vs Ally Financial Inc (ALLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Ally Financial Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Ally Financial Inc trades at $44.15 (market cap $13.32B). The key difference: Ally Financial Inc is far larger — about 6.1× ADMA Biologics Inc's market cap, and Ally Financial Inc pays a 2.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ALLY | |
|---|---|---|
Market Cap | $2.18B | $13.32B |
Sector | Health | Financials |
52-Week High | $20.38 | $47.25 |
52-Week Low | $7.60 | $35.96 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.
Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
